Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35


Renal abnormalities and their developmental origin.

Schedl A.

Nat Rev Genet. 2007 Oct;8(10):791-802. Review.


Molecular pathology and epidemiology of nephrogenic rests and Wilms tumors.

Fukuzawa R, Reeve AE.

J Pediatr Hematol Oncol. 2007 Sep;29(9):589-94. Review.


Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors.

Bjornsson HT, Brown LJ, Fallin MD, Rongione MA, Bibikova M, Wickham E, Fan JB, Feinberg AP.

J Natl Cancer Inst. 2007 Aug 15;99(16):1270-3. Epub 2007 Aug 8.


IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro.

Bendall SC, Stewart MH, Menendez P, George D, Vijayaragavan K, Werbowetski-Ogilvie T, Ramos-Mejia V, Rouleau A, Yang J, Bossé M, Lajoie G, Bhatia M.

Nature. 2007 Aug 30;448(7157):1015-21. Epub 2007 Jul 11.


Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.

Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, Angers S, Moon RT.

Science. 2007 May 18;316(5827):1043-6.


Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.

Fukuzawa R, Heathcott RW, More HE, Reeve AE.

J Clin Pathol. 2007 Sep;60(9):1013-6. Epub 2006 Dec 15. Erratum in: J Clin Pathol. 2007 Nov;60(11):1296.


Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.

Natrajan R, Reis-Filho JS, Little SE, Messahel B, Brundler MA, Dome JS, Grundy PE, Vujanic GM, Pritchard-Jones K, Jones C.

Cancer Res. 2006 Dec 1;66(23):11148-55.


Global variation in copy number in the human genome.

Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, González JR, Gratacòs M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, Tchinda J, Valsesia A, Woodwark C, Yang F, Zhang J, Zerjal T, Zhang J, Armengol L, Conrad DF, Estivill X, Tyler-Smith C, Carter NP, Aburatani H, Lee C, Jones KW, Scherer SW, Hurles ME.

Nature. 2006 Nov 23;444(7118):444-54.


Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.

Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, Dovey O, Gregory SG, Weber BL, Ashworth A, Grundy PE, Pritchard-Jones K, Jones C.

J Pathol. 2006 Sep;210(1):49-58.


Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor.

Breslow NE, Beckwith JB, Perlman EJ, Reeve AE.

Pediatr Blood Cancer. 2006 Sep;47(3):260-7.


Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.

Watanabe N, Nakadate H, Haruta M, Sugawara W, Sasaki F, Tsunematsu Y, Kikuta A, Fukuzawa M, Okita H, Hata J, Soejima H, Kaneko Y.

Genes Chromosomes Cancer. 2006 Jun;45(6):592-601.


Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA.

Little SE, Vuononvirta R, Reis-Filho JS, Natrajan R, Iravani M, Fenwick K, Mackay A, Ashworth A, Pritchard-Jones K, Jones C.

Genomics. 2006 Feb;87(2):298-306. Epub 2005 Nov 2.


Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.

Yuan E, Li CM, Yamashiro DJ, Kandel J, Thaker H, Murty VV, Tycko B.

Mol Cancer Res. 2005 Sep;3(9):493-502.


Wilms' tumour: connecting tumorigenesis and organ development in the kidney.

Rivera MN, Haber DA.

Nat Rev Cancer. 2005 Sep;5(9):699-712. Review. Erratum in: Nat Rev Cancer. 2005 Oct;5(10):835.


Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and beta-catenin.

Chen J, Wu A, Sun H, Drakas R, Garofalo C, Cascio S, Surmacz E, Baserga R.

J Biol Chem. 2005 Aug 19;280(33):29912-20. Epub 2005 Jun 20.


Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.

Ruteshouser EC, Hendrickson BW, Colella S, Krahe R, Pinto L, Huff V.

Genes Chromosomes Cancer. 2005 Jun;43(2):172-80.


Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.

Mummert SK, Lobanenkov VA, Feinberg AP.

Genes Chromosomes Cancer. 2005 Jun;43(2):155-61.


Epigenetic differences between Wilms' tumours in white and east-Asian children.

Fukuzawa R, Breslow NE, Morison IM, Dwyer P, Kusafuka T, Kobayashi Y, Becroft DM, Beckwith JB, Perlman EJ, Reeve AE.

Lancet. 2004 Feb 7;363(9407):446-51.


High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder.

Natrajan R, Louhelainen J, Williams S, Laye J, Knowles MA.

Cancer Res. 2003 Nov 15;63(22):7657-62.


Two molecular subgroups of Wilms' tumors with or without WT1 mutations.

Schumacher V, Schuhen S, Sonner S, Weirich A, Leuschner I, Harms D, Licht J, Roberts S, Royer-Pokora B.

Clin Cancer Res. 2003 Jun;9(6):2005-14.

Supplemental Content

Support Center